Skip to main content

Table 4 Survival of patients

From: An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents

  Median overall survival
  Time in months (95% CI)
Among the whole cohort (N = 198) 9.8 (8.1-11.4)
Among patients eligible for inclusion in a clinical trial (N = 131) 13.1 (11.2-17.8)